Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-501 + D745 + D150 + D029
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-501 + D745 + D150 + D029 is a fixed-dose oral combination regimen of four small molecule drugs under investigation, primarily aimed at metabolic disease (Type 2 diabetes). The composition includes CKD-501 (lobeglitazone sulfate)—a dual peroxisome proliferator-activated receptor α and γ (PPARα/γ) agonist, which acts as an insulin sensitizer[1][3][5]; D745, D150, and D029 are code designations, with trial context in diabetes and relevance to agents such as sitagliptin and metformin. This combination is used to compare or co-administer with CKD-383, potentially for additive/synergistic glycemic control or pharmacokinetic investigation[2]. CKD-501 is developed by Chong Kun Dang Pharmaceutical, with clinical trial sponsorship also by this company. The mechanism of action centers on the insulin sensitization from CKD-501 via dual PPARα/γ activation; other agents in the combination likely include a dipeptidyl peptidase-4 (DPP-4) inhibitor and a biguanide (metformin), given clinical context[2][3]. It is under Phase 1 investigation for safety and pharmacokinetics.
- Brand names
- CKD-501 + D759 + D150 + D029
- Other names
- CKD-501 + D745 + D150 + D029
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on CKD-501 + D745 + D150 + D029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-501 + D745 + D150 + D029.